Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis

– Kite’s Manufacturing Time for Yescarta® in the U.S. is Median of 7-Days from Start of Cell Enrichment to Harvest, with an Overall 16-Day Turnaround Time (Leukapheresis to Product Release) –

– CIBMTR Analysis Finds Median ‘Vein-to-Vein’ Time (Leukapheresis to Infusion) in Real World Setting is 27-Days for Yescarta in the U.S. –

– In Same Analysis, Shorter Vein-to-Vein Time Associated with 60% Complete Response Rate in Patients Treated with Yescarta at Median Follow-Up of 24.2 Months –

Related Keywords

California ,United States ,Foster City ,American ,Chris Mcdonald ,Santa Monica ,Frederickl Locke ,Gilead Sciences ,Marrow Transplant Research ,National Marrow Donor Program ,International Blood ,College Of Wisconsin ,Gilead Sciences Inc ,Exchange Commission ,American Society Of Hematology ,Gilead Company ,Cellular Immunotherapy At Moffitt Cancer Center ,Research Database ,Department Of Blood ,Gilead Company Nasdaq ,Annual Meeting ,Marrow Transplant ,Moffitt Cancer ,Global Head ,Technical Operations ,Product Release ,Chimeric Antigen Receptor ,Release Syndrome ,Risk Evaluation ,Mitigation Strategy ,Medical College ,Private Securities Litigation Reform Act ,Quarterly Report ,